Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24207038 | 0.91 | USP30 (0.44) | KDM4ECHRM2CHRM1CHRM4MAPT | |
| SCHEMBL27345165 | 0.91 | USP30 (0.44) | KDM4ECHRM2CHRM1CHRM4MAPT | |
| SCHEMBL26969675 | 0.91 | USP30 (0.44) | KDM4ECHRM2CHRM1CHRM4MAPT | |
| SCHEMBL21876910 | 0.88 | CHRM4 (0.47) | KDM4ECHRM2CHRM1CHRM4MAPT | |
| SCHEMBL24696583 | 0.86 | KDM4E (0.44) | KDM4ECHRM2CHRM1CHRM4MAPT | |
| SCHEMBL24207041 | 0.84 | NOTUM (0.43) | KDM4ECHRM2CHRM1CHRM4MAPT | |
| SCHEMBL24319568 | 0.84 | KDM4E (0.42) | KDM4ECHRM2CHRM1CHRM4MAPT | |
| SCHEMBL24319287 | 0.82 | KDM4E (0.41) | KDM4ECHRM2CHRM1CHRM4MAPT | |
| SCHEMBL26783647 | 0.81 | ALDH1A1 (0.43) | KDM4EKMT2AALDH1A1 | |
| SCHEMBL27194285 | 0.81 | MEN1 (0.40) | KDM4EKMT2AMEN1HTR6MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448389-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4584258-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12180193-B2 | Accelerating fibrosarcoma protein degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240425523-A1 | Compounds for the Degradation of EGFR Kinase | BEONE MEDICINES I GMBH (CH) | 2024-12-26 | — | — | US | disclosed |
| US-12156916-B2 | Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| CN-118812564-A | EGFR-targeting proteolytic targeting chimeras, compositions and uses thereof | 厦门宝太生物科技股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240156967-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240156968-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| CN-117062814-A | Compounds that rapidly accelerate fibrosarcoma protein degradation and related methods of use | 阿维纳斯运营公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-116745295-A | BRM targeting compounds and related methods of use | 普莱鲁德疗法有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4204418-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230083376-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS, INCORPORATED | 2023-03-16 | — | — | US | disclosed |
| US-20230081501-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022047145-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022047145-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230081501-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | KDM4E 2141/4885CHRM2 4689/4885CHRM1 4729/4885 |
| US-12156916-B2 | Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | BRAF, ARAF, RAF1 | KDM4E 1935/4885CHRM2 2927/4885CHRM1 2550/4885 |
| US-12180193-B2 | Accelerating fibrosarcoma protein degrading compounds and associated methods of use | CRBN, RBX1, ARAF | KDM4E 2141/4885CHRM2 4645/4885CHRM1 4700/4885 |
| US-20240425523-A1 | Compounds for the Degradation of EGFR Kinase | EGFR, ERBB2, ERBB3 | KDM4E 1516/4885CHRM2 4788/4885CHRM1 4686/4885 |
| US-20240156968-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARAF, BRAF, HRAS | KDM4E 3111/4885CHRM2 4763/4885CHRM1 4798/4885 |
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | KDM4E 2141/4885CHRM2 4689/4885CHRM1 4729/4885 |
| US-20230083376-A1 | BRM Targeting Compounds And Associated Methods Of Use | ADRM1, BRDT, RBX1 | KDM4E 2075/4885CHRM2 3539/4885CHRM1 3642/4885 |
| US-20240156967-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | BRAF, ARAF, RAF1 | KDM4E 2043/4885CHRM2 3128/4885CHRM1 2776/4885 |
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARAF, BRAF, HRAS | KDM4E 3111/4885CHRM2 4763/4885CHRM1 4798/4885 |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | KDM4E 2075/4885CHRM2 3539/4885CHRM1 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.